Mirum Pharmaceuticals

210 articles about Mirum Pharmaceuticals

• Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals

  5/23/2022

  Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it has acquired Satiogen Pharmaceuticals, Inc., a San Diego-based company. Satiogen, now a wholly-owned Mirum subsidiary, was an existing licensing partner for LIVMARLI® (maralixibat) oral solution and volixibat.

• Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - May 18, 2022

  5/18/2022

  Mirum Pharmaceuticals, Inc. announced that it will participate in the following upcoming virtual investor conferences.

• Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 11, 2022

  5/11/2022

  Mirum Pharmaceuticals, Inc. announced that on May 10, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 178,000 shares of common stock and 52,677 restricted stock units to 18 new employees under Mirum’s 2020 Inducement Plan.

• Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

  5/5/2022

  Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the first quarter ended March 31, 2022 and provided a business update.

• Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022

  5/2/2022

  Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter financial results on Thursday, May 5, 2022.

• Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 08, 2022

  4/8/2022

  Mirum Pharmaceuticals, Inc. announced that on April 8, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 25,500 shares of common stock and 12,650 restricted stock units to five new employees under Mirum’s 2020 Inducement Plan.

• Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 11, 2022

  3/11/2022

  Mirum Pharmaceuticals, Inc. announced that on March 10, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 16,350 shares of common stock and 8,150 restricted stock units to two new employees under Mirum’s 2020 Inducement Plan.

• Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

  3/9/2022

  Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2021 and provided a business update.

• Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End Business Results for 2021 and Host Conference Call on March 9, 2022

  3/2/2022

  Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2021 results on Wednesday, March 9, 2022.

• Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference

  2/9/2022

  Mirum Pharmaceuticals, Inc. announced that it will present during the SVB Leerink 11th Annual Global Healthcare Conference taking place virtually February 14-18, 2022.

• Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 11, 2022

  1/11/2022

  Mirum Pharmaceuticals, Inc. announced that on January 10, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 51,700 shares of common stock and 7,150 restricted stock units to five new employees under Mirum’s 2020 Inducement Plan.

• Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones

  1/11/2022

  Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today provided a corporate update and highlighted key 2022 milestones in conjunction with its presentation at the 40th Annual J.P. Morgan Virtual Healthcare Conference.

• Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

  1/4/2022

  Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will present at the annual J.P. Morgan Healthcare Conference taking place virtually January 10-13, 2022.

• Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index

  12/15/2021

  Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it has been selected for addition to the NASDAQ Biotechnology Index.

• LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at NASPGHAN Annual Meeting 2021

  12/13/2021

  Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) presented new analyses from LIVMARLI™ (maralixibat) oral solution clinical studies during the North American Society for Pediatric Gastroenterology Hepatology and Nutrition Annual Meeting, taking place virtually December 12-18, 2021.

• Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting

  12/6/2021

  Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that five posters featuring data on LIVMARLI™ (maralixibat) oral solution will be presented at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting taking place virtually December 12-18, 2021.

• Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

  11/22/2021

  Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in the following upcoming virtual investor conferences: Piper Sandler 33rd Annual Virtual Healthcare Conference on November 30, 2021.

• 

  Clinical Catch-Up: November 15-19

  11/22/2021

  With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look.

• Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher

  11/17/2021

  Mirum Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (“PRV”) for $110 million.

• Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome

  11/15/2021

  Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that a new analysis comparing pooled LIVMARLI™ (maralixibat) oral solution clinical trial data with a natural history cohort was presented at the American Association for the Study of Liver Diseases annual congress, The Liver Meeting®.